Loading…
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $176M | $-2M | $78M | $-28M | 15.6% | 12.4% | - |
| 2024 | $157M | $-70M | $-115M | $-38M | -28.6% | -7.1% | - |
| 2023 | $169M | $-51M | $-100M | $-46M | -20.4% | -28.9% | - |
| 2022 | $237M | $-6M | $-37M | $-26M | -6.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 237.28 | 168.66 | 156.77 | 176.18 |
| Cost Of Revenue | 133.40 | 93.33 | 87.11 | 93.12 |
| Gross Profit | 103.87 | 75.33 | 69.66 | 83.05 |
| Operating Expense | 135.78 | 126.30 | 127.52 | 119.86 |
| Operating Income | -31.90 | -50.97 | -57.86 | -36.81 |
| EBITDA | -6.19 | -51.15 | -69.61 | -2.10 |
| EBIT | -28.95 | -78.63 | -100.37 | -29.81 |
| Pretax Income | -35.09 | -84.21 | -104.35 | -32.17 |
| Tax Provision | 2.24 | 0.34 | 0.36 | 1.80 |
| Net Income | -37.33 | -99.59 | -114.76 | 78.30 |
| Net Income Common Stockholders | -45.33 | -107.59 | -122.76 | 70.30 |
| Total Expenses | 269.18 | 219.63 | 214.63 | 212.98 |
| Interest Expense | 6.14 | 5.58 | 3.98 | 2.36 |
| Research And Development | 15.72 | 18.04 | 17.71 | 17.04 |
| Selling General And Administration | 120.06 | 108.26 | 109.81 | 102.82 |
| Normalized EBITDA | -14.66 | -17.83 | -34.21 | -11.89 |
| Normalized Income | -44.03 | -58.24 | -76.73 | -41.71 |
| Basic EPS | -0.93 | -2.21 | -2.49 | 1.40 |
| Diluted EPS | -0.93 | -2.21 | -2.49 | 1.40 |
| Tax Effect Of Unusual Items | 1.78 | -7 | -7.44 | 2.06 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | 8.47 | -33.31 | -35.41 | 9.80 |
| Total Unusual Items Excluding Goodwill | 8.47 | -33.31 | -35.41 | 9.80 |
| Net Income From Continuing Operation Net Minority Interest | -37.33 | -84.56 | -104.71 | -33.97 |
| Reconciled Depreciation | 22.77 | 27.49 | 30.76 | 27.71 |
| Reconciled Cost Of Revenue | 133.40 | 93.33 | 87.11 | 93.12 |
| Net Interest Income | -6.14 | -5.58 | -3.98 | -2.36 |
| Net Income From Continuing And Discontinued Operation | -37.33 | -99.59 | -114.76 | 78.30 |
| Total Operating Income As Reported | -31.90 | -100.54 | -121.67 | -36.81 |
| Diluted Average Shares | 48.99 | 48.74 | 49.35 | 50.07 |
| Basic Average Shares | 48.99 | 48.74 | 49.35 | 50.07 |
| Diluted NI Availto Com Stockholders | -45.33 | -107.59 | -122.76 | 70.30 |
| Preferred Stock Dividends | 8 | 8 | 8 | 8 |
| Net Income Including Noncontrolling Interests | -37.33 | -99.59 | -114.76 | 78.30 |
| Net Income Discontinuous Operations | 0 | -15.03 | -10.05 | 112.27 |
| Net Income Continuous Operations | -37.33 | -84.56 | -104.71 | -33.97 |
| Other Income Expense | 2.95 | -27.67 | -42.51 | 7 |
| Other Non Operating Income Expenses | -5.52 | 5.65 | -7.10 | -2.80 |
| Special Income Charges | 0 | -43.89 | -45.30 | 0 |
| Other Special Charges | 0 | -5.68 | -18.50 | 0 |
| Impairment Of Capital Assets | 0 | 49.57 | 63.81 | 0 |
| Gain On Sale Of Security | 8.47 | 10.58 | 9.89 | 9.80 |
| Net Non Operating Interest Income Expense | -6.14 | -5.58 | -3.98 | -2.36 |
| Interest Expense Non Operating | 6.14 | 5.58 | 3.98 | 2.36 |
| Operating Revenue | 237.28 | 168.66 | 156.77 | 176.18 |
Industrials sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Cryoport, Inc.this co. | CYRX | $492M | - | 1.06 | 15.6% | -89.47 |
| Ennis, Inc. | EBF | $521M | 12.41 | 1.69 | 13.3% | 7.03 |
| Titan International, Inc. | TWI | $512M | - | 0.99 | -12.2% | 11.47 |
| Pangaea Logistics Solutions Ltd. | PANL | $496M | 25.33 | 1.15 | 4.1% | 10.08 |
| Insteel Industries Inc. | IIIN | $490M | 11.96 |
| 1.32 |
| 11.0% |
| 6.31 |
| Orion Group Holdings, Inc. | ORN | $483M | 54.59 | 3.01 | 1.6% | 15.30 |
| Acacia Research Corporation | ACTG | $479M | 22.55 | 0.88 | 3.7% | 5.12 |
| Titan Machinery Inc. | TITN | $474M | - | 0.80 | -9.4% | 36.31 |
| The Manitowoc Company, Inc. | MTW | $467M | 65.05 | 0.66 | 1.0% | 7.65 |
| Peer Median | - | 23.94 | 1.07 | 2.6% | 8.87 | |